The current stock price of MYO is 0.9882 USD. In the past month the price decreased by -7.64%. In the past year, price decreased by -84.82%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 184 full-time employees. The company went IPO on 2017-06-12. The firm develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
MYOMO INC
137 Portland Street, 4th Floor
Boston MASSACHUSETTS 02114 US
CEO: Paul R. Gudonis
Employees: 184
Phone: 16179969058
Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 184 full-time employees. The company went IPO on 2017-06-12. The firm develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
The current stock price of MYO is 0.9882 USD. The price increased by 0.82% in the last trading session.
MYO does not pay a dividend.
MYO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
The Revenue of MYOMO INC (MYO) is expected to grow by 32% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
The outstanding short interest for MYOMO INC (MYO) is 9.2% of its float.
ChartMill assigns a technical rating of 2 / 10 to MYO. When comparing the yearly performance of all stocks, MYO is a bad performer in the overall market: 93.98% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to MYO. MYO has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months MYO reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS decreased by -26.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.11% | ||
| ROE | -52.93% | ||
| Debt/Equity | 0.22 |
9 analysts have analysed MYO and the average price target is 5.1 USD. This implies a price increase of 416.09% is expected in the next year compared to the current price of 0.9882.
For the next year, analysts expect an EPS growth of -117.45% and a revenue growth 32% for MYO